SPRO Jul 2024 2.500 call
| Previous close | 0.0900 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 570 |
GlobeNewswireSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE)
Simply Wall St.Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 23% in the last...
